Assetmark Inc. Has $12.81 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Assetmark Inc. boosted its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 12.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 152,810 shares of the medical equipment provider's stock after buying an additional 16,986 shares during the quarter. Assetmark Inc.'s holdings in Boston Scientific were worth $12,806,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Verdence Capital Advisors LLC boosted its position in shares of Boston Scientific by 4.3% in the 3rd quarter. Verdence Capital Advisors LLC now owns 4,007 shares of the medical equipment provider's stock valued at $336,000 after purchasing an additional 165 shares during the period. Holistic Planning LLC purchased a new stake in Boston Scientific in the 3rd quarter worth about $213,000. CWA Asset Management Group LLC purchased a new stake in Boston Scientific in the 3rd quarter worth about $666,000. Hollencrest Capital Management lifted its stake in Boston Scientific by 12.4% in the 3rd quarter. Hollencrest Capital Management now owns 1,328 shares of the medical equipment provider's stock worth $111,000 after acquiring an additional 147 shares in the last quarter. Finally, Capital Performance Advisors LLP acquired a new stake in Boston Scientific during the third quarter valued at $30,000. Institutional investors own 89.07% of the company's stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of several recent research reports. StockNews.com downgraded shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Monday, November 4th. Needham & Company LLC reiterated a "hold" rating on shares of Boston Scientific in a report on Thursday, October 31st. Mizuho raised their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company an "outperform" rating in a research note on Thursday, October 24th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Boston Scientific from $73.00 to $78.00 and gave the company a "hold" rating in a report on Thursday, July 25th. Finally, Raymond James raised their price target on Boston Scientific from $91.00 to $94.00 and gave the company a "strong-buy" rating in a research report on Wednesday, September 4th. Four investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $93.39.

Boston Scientific Trading Up 0.3 %

BSX traded up $0.23 during trading on Monday, reaching $88.48. 3,936,818 shares of the company's stock were exchanged, compared to its average volume of 6,082,132. The company's fifty day moving average price is $84.61 and its 200-day moving average price is $79.05. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.48. Boston Scientific Co. has a fifty-two week low of $52.99 and a fifty-two week high of $88.94. The firm has a market capitalization of $130.40 billion, a PE ratio of 73.17, a P/E/G ratio of 2.60 and a beta of 0.79.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The firm had revenue of $4.21 billion during the quarter, compared to analyst estimates of $4.04 billion. During the same quarter in the previous year, the business earned $0.50 EPS. The business's quarterly revenue was up 19.3% compared to the same quarter last year. As a group, equities analysts forecast that Boston Scientific Co. will post 2.46 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the company's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $85.00, for a total value of $11,264,795.00. Following the completion of the sale, the executive vice president now owns 160,467 shares in the company, valued at $13,639,695. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the company's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $85.00, for a total value of $11,264,795.00. Following the completion of the sale, the executive vice president now owns 160,467 shares in the company, valued at $13,639,695. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael F. Mahoney sold 162,777 shares of the company's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the completion of the sale, the chief executive officer now owns 1,572,096 shares of the company's stock, valued at approximately $133,046,484.48. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 309,270 shares of company stock valued at $26,196,718. Company insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.